Andrew I Lazarovits

This inventor holds 5 USPTO granted patents. Top assignees: Research Corporation Technologies, Inc., Alimunne, L.l.c., Other. Active years: 2000-2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew I Lazarovits. Retrieved from https://idiyas.com/inventor/andrew-i-lazarovits

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5

% Patents Active = 80.0

Average Co-Inventor Count = 2.0

ph-index = 3

Forward Citations = 36(Granted Patents)

Company Filing History:

3 out of 366

Research Corporation Technologies, Inc.

1 out of 834,570

Other

patents

Years Active: 2000-2007

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7160987 - Use of anti-CD45 leukocyte antigen antibodies for immunomodulation (2007-01-09),

2. 6379668 - Use of anti-CD45 leukocyte antigen antibodies for immunomodulation (2002-04-30),

3. 6106834 - Use of anti-CD45 leukocyte antigen antibodies for immunomodulation (2000-08-22),

4. 6099838 - Pharmaceutical compositions comprising anti-CD45RB antibodies for the (2000-08-08),

5. 6024957 - Immunomodulators and methods for the prevention and reversal of organ (2000-02-15),

Title: The Innovative Contributions of Andrew I Lazarovits

Introduction

Andrew I Lazarovits is a notable inventor based in London, Canada. He has made significant contributions to the field of immunology, particularly through his innovative patents. With a total of 5 patents, Lazarovits has focused on advancing therapies for transplant rejection and autoimmune diseases.

Latest Patents

Among his latest patents is a method for the prevention or reversal of transplant rejection, which utilizes anti-CD45 leukocyte antigen antibodies for immunomodulation. This method involves administering compounds such as monoclonal antibodies that specifically bind to preselected CD45R leukocyte antigens, including the CD45RB epitope. This innovative approach aims to enhance therapeutic options for patients facing transplant challenges and autoimmune disorders.

Career Highlights

Lazarovits has worked with several prominent organizations throughout his career. Notably, he has been associated with Research Corporation Technologies, Inc. and Alimunne, L.L.C. His work in these companies has allowed him to develop and refine his groundbreaking ideas in immunology.

Collaborations

One of his notable collaborators is Sibrand Poppema. Their partnership has contributed to the advancement of research in the field, further enhancing the impact of Lazarovits' inventions.

Conclusion

Andrew I Lazarovits stands out as an influential inventor in the realm of immunology. His innovative patents and collaborations have paved the way for new therapeutic strategies in managing transplant rejection and autoimmune diseases. His contributions continue to inspire advancements in medical science.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]